Reply  by Thiele, Holger
R1
2
N
B
T
N
i
i
t
i
T
a
e
b
a
p
f
b
t
N
s
c
d
s
m
p
i
t
t
a
m
a
m
i
i
p
b
t
r
2
t
i
N
t
b
m
r
“
c
r
h
l
i
a
z
h
h
e
c
o
w
b
a
t
t
N
c
H
w
f
p
p
*
*
I
V
1
C
E
R
1
2
3
R
W
t
d
A
L
m
1067JACC Vol. 56, No. 13, 2010 Correspondence
September 21, 2010:1065–70EFERENCES
. Raber L, Juni P, Loffel L, et al. Impact of stent overlap on angiographic
and long-term clinical outcome in patients undergoing drug-eluting
stent implantation. J Am Coll Cardiol;55:1178–88.
. Windecker S, Remondino A, Eberli FR, et al. Sirolimus-eluting and
paclitaxel-eluting stents for coronary revascularization. N Engl J Med
2005;353:653–62.
-Acetylcysteine Somewhere
etween Scylla and Charybdis
hiele et al. (1) report a study dealing with the impact of
-acetylcysteine (NAC) administered simultaneously on prevent-
ng iodinated contrast agent-induced nephropathy and reperfusion
njury in patients with ST-segment elevation myocardial infarction
reated by percutaneous coronary intervention (PCI). The study
ncluded 126 patients compared with a placebo-treated group.
heir results as well as conclusions generate many noteworthy
ssociations.
Free oxygen radicals are regarded as variable typically involved
ither in reperfusion of previously ischemic tissue anywhere in the
ody or in specific interaction between the iodinated contrast agent
nd the filtration capacity of the kidney, with the latter being most
ronounced with previous kidney injury.
As a result, the exact mode of action of NAC (defense against
ree oxygen radicals) in the LIPSIA-N-ACC (Prospective, single-
lind, placebo-controlled, randomized Leipzig Immediate Percu-
aneouS coronary Intervention Acute myocardial infarction
-ACC) trial still remains unclear. First, most importantly, it
hould be taken into account that all patients had normal serum
reatinine level, perhaps a crucial fact for further evaluation. A
ifferent study design including patients with a priori elevated
erum creatinine levels (roughly at least 140 mol/l) would be
ore appropriately representative by making the same size of the
atient group sufficient for final statistical analysis. Even so, the
ncidence of contrast agent-induced nephropathy incidence in
he NAC-treated arm of the LIPSIA-N-ACC trial was reported
o be lower by 6% when compared with the placebo group. Second,
nother fact raising some doubt is the selected dose of NAC: 1,200
g of NAC before PCI cannot be regarded as a high dose even if
dministered intravenously. In experimental studies, an approxi-
ate dose of 100 mg NAC/kg body weight has been used before
nduction of injury (i.e., this is de facto the total dose of NAC used
n the present trial including doses administered within 48 h
ost-procedurally). Third, likewise, the distribution of NAC
etween the 2 target organs remains unclear: the kidney exposed to
he burden of the iodinated contrast agent versus the ischemic/
eperfused myocardium (i.e., the proportion of NAC entering the
aforementioned organs and even more so, after recirculation
hrough the pulmonary vessel bed: a Killip class 2 was reported
n 11% of the NAC group and in 14% of the placebo group). The
AC bolus and, actually, the whole dose administered is figura-
ively somewhere between Scylla and Charybdis, with the former
eing nephron stress and the latter ischemic and reperfusion
yocardial injury. Fourth, the enigma for researchers to be yet
esolved continues to be which “high” dose of NAC is actually
high” in terms of being functionally adequate for both the organ iompartments in question. The authors (1) report a 20%
eduction of oxidative stress markers in the NAC group: this is,
owever, a biochemical parameter, perhaps not yet reaching a
evel high enough to have a functional or possibly structural
mpact on the injured myocardial area. Fortunately enough,
lmost all patients were receiving angiotensin-converting en-
yme inhibitors/angiotensin II type 1 antagonists and statins—
opefully comparable?—in both study groups. Fifth, earlier
uman studies (for details, see appropriate references in Thiele
t al. [1]) used different types of myocardial reperfusion/
oronary artery recanalization: fibrinolysis (2) involving opening
f the artery by gradual dissolution of a fresh red thrombus,
hereas current PCI is “an instantaneous switch for coronary
lood flow from the closed to open position.” Sixth, the
forementioned makes it unclear whether mode NAC action on
he myocardial microvasculature is the same in both reperfusion
echniques. Finally, judging by experimental animal studies,
AC seems to exert more beneficial effects on the filtration
apacity of the kidney in its more developed injury (3).
The reader could now perhaps say the study simply failed.
owever, from a scientific point of view, I personally feel this
ell-designed study has provided many provoking stimuli for
urther research and definitely is not to be perceived as a breaking
oint for making indiscriminate decisions in our current clinical
ractice.
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eply
e thank Prof. Sochman for his interest in our paper (1) and agree
hat the exact mode of action of N-acetylcysteine (NAC) for the
efense against free oxygen radicals—as shown in our LIPSIA-N-
CC (Prospective, single-blind, placebo-controlled, randomized
eipzig Immediate PercutaneouS coronary Intervention Acute
yocardial infarction N-ACC) trial—remains unclear. However,n contrast to the first of 7 statements by Prof. Sochman, not all
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September 21, 2010:1065–70atients in our trial had normal serum creatinine at baseline. In the
verall study 19% had impaired creatinine clearance at baseline of
60 ml/min, and there were no or even numerically worse effects
25% vs. 13%) of NAC on contrast agent-induced nephropathy
CIN) in this specific subgroup—demonstrated in Figure 2 of the
ublication (1). Performing a clinical trial with selection of patients
ith elevated serum creatinine 140 mol/l is not feasible,
ecause the serum creatinine is usually not known at hospital
resentation and waiting until laboratory results are available is
ertainly not possible, given the strong relationship of time-to-
eperfusion on myocardial salvage (2). Although, overall, there was
6% CIN reduction by NAC, the lack of effect in patients with
mpaired renal function raises doubts that there might be effects in
ifferent patient groups. Second, regarding the NAC dose, we
elieve that in total 6,000 mg is a high dose as shown previously
3), and there are currently no clinical trials that have tested higher
oses (4). Nevertheless, testing an even higher dose might be
orth study. Third, the distribution of NAC between the 2 target
rgans in our trial is indeed not entirely clear. However, local drug
oncentration measurement is clinically not feasible, and also local
rug application into the renal or the infarct-related artery is
onsidered impractical. Given the fast distribution through the
irculation, any relevant impairment of drug distribution is un-
ikely. Fourth, the 20% reduction in oxidative stress is interesting;
owever, its effect on clinically relevant parameters such as myo-
ardial salvage or renal function remains unclear. Because the
istribution of angiotensin-converting enzyme inhibitors, angio-
ensin II type 1 antagonists, and statins was similar between both
roups (Table 1 of Thiele et al. [1]), effects on oxidative stress are
nlikely. Fifth, earlier clinical trials indeed did not use angioplasty,
hich is the state-of-the-art technique. Sixth, whether the mode
f action is dependent on reperfusion type cannot be answered
ithout comparative studies. However, these earlier fibrinolytic
rials used much more insensitive surrogate parameters, and the
ample size was very small, which raises questions of power.
In general, we agree with Prof. Sochman that our LIPSIA-N-
CC trial should stimulate further research regarding oxidative
tress and also a large-scale clinical trial of NAC for CIN
revention. However, we strongly believe, on the basis of our
esults, that a general application of NAC in infarction patients
annot be recommended.
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ssessing Clinical Utility of
arotid Intima-Media Thickness
n the Basis of Reclassification
lthough Nambi et al. (1) report significant net reclassification
NRI) with the use of carotid ultrasound of 9.9% in the overall
RIC (Atherosclerosis Risk In Communities) cohort and 21.7%
n the intermediate-risk group (5% to 20% 10-year risk) and
onclude potential clinical utility in predicting cardiovascular
vents, the actual NRI tables for those with and without events
eed to be presented for full assessment of clinical utility. The NRI
s determined by: 1) movement to higher risk categories among
hose with events; and 2) movement to lower risk categories among
hose without events (2). Although both components of the NRI
re of interest, reclassification rates among those with events
epresent the more clinically relevant measure. However, Nambi et
l. (1) do not provide separate reclassification tables for those with
nd without events to assess where the reclassification is occurring.
urthermore, 2 categories were used for intermediate risk (5% to
0% and 10% to 20%), and it is unclear what drove the net
eclassification of 21% within this group: movement to 20%
redicted risk in those with events, movement to 5% predicted
isk in those without events, or movement within the 2 interme-
iate risk categories. Showing the actual NRI tables as described by
encina et al. (2) would aid clinical interpretation. Finally, coro-
ary revascularization and silent MI comprised 43% of the end
oints analyzed in the ARIC cohort; however, treatment changes
ould most likely occur for those with events who were reclassified
pward to 20% predicted 10-year risk of hard end points alone.
omplete assessment of clinical utility on the basis of improved
eclassification can only be assessed by showing the full NRI tables
or those with and without hard end points.
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